American Journal of Hematology
Nov 10, 2025, 10:37
Should Transferrin Saturation Guide HFE-Hemochromatosis Therapy?
American Journal of Hematology shared on X:
“In HFE-hemochromatosis, transferrin saturation above ~75% suggests harmful non-transferrin-bound iron levels. Due to assay limits for NTBI, monitoring TSAT levels during maintenance therapy may help and should guide care until accurate NTBI tests exist.”
Title: Should Serum Transferrin Saturation Be Included as a Therapeutic Target in Addition to Serum Ferritin in Treating HFE-Hemochromatosis?
Authors: Nils Thorm Milman, Christina Ellervik
Read the full article here.
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 13:32W David Freeman։ The Mechanical Penumbra in Intracerebral Hemorrhage and Its Potential for Tissue Recovery
-
Oct 9, 2026, 13:11Ayshathul Noora։ Carbetocin vs Oxytocin in Preventing Postpartum Hemorrhage
-
Oct 9, 2026, 13:07The Rebalanced Patient: New Therapies and New Thrombotic Risks in Hemophilia
-
Oct 9, 2026, 12:48Santiago Cepeda Chafla: CereBleed Simplifies Brain Hemorrhage Assessment
-
Oct 9, 2026, 12:34Abdul Muqtadir Abbasi: Pancytopenia Is a Finding, Not a Diagnosis
-
Oct 9, 2026, 12:24Mercy Lung’aho: When Diet Quality and Nutritional Biomarkers Tell Different Stories
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care
-
Oct 9, 2026, 12:14Brittany Busse: A New Focus on Iron Deficiency Before Anemia
-
Oct 9, 2026, 12:13Akshat Jain: A New Textbook Bringing Global Perspectives on Sickle Cell Disease